On the other hand, Guidetti et al. proved that exogenous recombinant decorin or de novo expression of decorin could downregulate the endogenous expression of proangiogenic factor, VEGF, as well as that of fibroblast growth factor-2 (FGF-2) [36] and suppressed the tumorigenicity of human colon carcinoma cells both in vitro and in vivo. Here, DCN is linked to colon carcinoma.